WO2009043986A1 - Reactif pseudo peptidique trifonctionnel, ses utilisations et applications - Google Patents
Reactif pseudo peptidique trifonctionnel, ses utilisations et applications Download PDFInfo
- Publication number
- WO2009043986A1 WO2009043986A1 PCT/FR2008/001007 FR2008001007W WO2009043986A1 WO 2009043986 A1 WO2009043986 A1 WO 2009043986A1 FR 2008001007 W FR2008001007 W FR 2008001007W WO 2009043986 A1 WO2009043986 A1 WO 2009043986A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- unit
- trifunctional
- reagent
- function
- luminescent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- NKNMBUYUVXSCIZ-HEVIKAOCSA-N CCSSC[C@@H](C(N)=O)NC([C@H](CCCCNC(CONC(OCC1c2ccccc2-c2c1cccc2)=O)=O)NC(COCCOCCNC(COCCOCCN)=O)=O)=O Chemical compound CCSSC[C@@H](C(N)=O)NC([C@H](CCCCNC(CONC(OCC1c2ccccc2-c2c1cccc2)=O)=O)NC(COCCOCCNC(COCCOCCN)=O)=O)=O NKNMBUYUVXSCIZ-HEVIKAOCSA-N 0.000 description 1
- UORUIBQHOCCKKF-UHFFFAOYSA-N O=C(CONC(OCC1c2ccccc2-c2ccccc12)=O)ON(C(CC1)=O)C1=O Chemical compound O=C(CONC(OCC1c2ccccc2-c2ccccc12)=O)ON(C(CC1)=O)C1=O UORUIBQHOCCKKF-UHFFFAOYSA-N 0.000 description 1
- XQLJEKGEUGUEJZ-UHFFFAOYSA-N OC(CONC(OCC1c(cccc2)c2-c2c1cccc2)=O)=O Chemical compound OC(CONC(OCC1c(cccc2)c2-c2c1cccc2)=O)=O XQLJEKGEUGUEJZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
Definitions
- the present invention relates to a trifunctional pseudopeptide reagent, for its various uses, in particular for the preparation of luminescent reagents or bioconjugates, optionally luminescent, the use of these reagents and bioconjugates for the functionalization of solid supports, as well as for the use of the solid supports thus functionalized for the detection of molecules of interest.
- bioconjugates derived from biopolymers involve being able to covalently (reversibly or non-reversibly) attaching these bioconjugates to a second molecular architecture (biopolymer, solid support,. ..) and to detect and / or quantify them accurately (optical detection, radioactive, ).
- a second molecular architecture biopolymer, solid support,. ..
- it is essential to have tools for effectively combining a biopolymer with other (macro) molecules without significantly altering the properties of each of the partners involved in the resulting and targeted molecular architecture.
- bifunctional cross-linking reagents For this purpose, many small bifunctional molecules (better known as "bifunctional cross-linking reagents") have been developed. A large number are marketed by Pierce. However, it is interesting to note that several academic groups continue to work on the development of new bifunctional reagents that are increasingly sophisticated and allow the development of ever more complex bioconjugates.
- the sulfo-SBED is not entirely satisfactory inasmuch as it is not possible to modulate the hydrophobic / hydrophilic nature and especially the third functional unit (ie biotin) allows only strong interaction (quasi -covalent) with partners previously conjugated to avidin (glycoprotein) or streptavidin, which greatly limits its use.
- trifunctional reagents for preparing bioconjugates consisting of a trifunctional central unit selected from triaminobenzene, tricarboxybenzene, dicarboxyaniline and diaminobenzoic acid, on which three affinity ligands, a biomolecule-reactive group and an effector agent are attached via three distinct linker arms.
- This reagent has the disadvantage of having a trifunctional central unit consisting of at least two identical chemical functions (ie, carboxylic acid or amine functions) which restricts the choice of the complementary functions carried by the connecting arms which may have a limiting effect.
- trifunctional reagents comprising three distinct functional poles, namely a luminescent group (L), a molecule (B) selected from the analyte to be detected, an analogue or a fragment thereof and finally a function ensuring the attachment of said trifunctional reagent to the surface of a solid support
- L luminescent group
- B molecule
- the present invention therefore firstly relates to a trifunctional pseudopeptide reagent, characterized in that it comprises at least the following three reactive structural units A, B and C:
- a unit A consisting of a hydrophilic chain of pseudopoly (ethylene glycol) (pseudo-PEG chain) interrupted by at least one amide function and having two ends E1 and E2, said E1 end being free and having a pattern terminal selected from amino group (-NH 2 ), activated carbamates and activated esters, and said E2 end having a terminal carbon atom carrying a carbonyl function, said carbon atom being engaged in an amide function (-C (O) -NH-) formed with the nitrogen atom of an ⁇ -amine function carried by the unit B;
- a unit B consisting of an amino acid chosen from ⁇ -amino acids of the L, D series and their racemic mixtures, said amino acid having on its side chain at least one oxyamine function protected by a protecting group or at least one minus a masked aldehyde function; and (c) a unit C consisting of an amino acid selected from ⁇ -amino acids of the L, D series and their racemic mixtures, said amino acid having on its side chain at least one thiol, maleimide, iodoacetyl, azide unit, true alkyne, phosphane or cyclooctyne; said units B and C being linked to one another via an amide function formed between the carbon atom carrying the carbonyl function of the ⁇ -amino acid constituting the unit B and the nitrogen atom of the ⁇ -amine function of the ⁇ -amino acid constituting the unit C.
- the main originality of these structures lies in the combination of amino acids (natural or modified) protected on their side chains by selected protective groups, and a functionalized pseudo-PEG chain whose length is easily adjustable. Even if the presence of several chemical functions (protected or not) necessarily entails problems during the preparation of these reagents (incompatibilities between functions, degradation and / or premature deprotection of certain protective groups, ...), the structure segmented into three Separate structural units (prepared independently of each other and then coupled together in the final steps of developing the trifunctional reagent) allows for a highly convergent synthesis strategy that minimizes the simultaneous presence of incompatible chemical motifs between them. Furthermore, a large structural diversity (modulation of geometry, length, physicochemical properties and solubility in particular, etc.) is accessible by modifying only one of the three structural units of the trifunctional reagent.
- the term "pseudo" -PEG string a string having great similarities of structure with the PEG chain: but which differs by the presence of one or more functional groups (ester, amide, carbamate, urea, ...) within it.
- the term "true” alkyne is understood to mean an alkyne whose triple bond is monosubstituted by a R: R 3 group.
- the three reactive structural units constituting the trifunctional reagents according to the present invention make it possible to carry out reactions totally chemo-selective under mild conditions (especially in aqueous media in which biopolymers are soluble).
- the activated carbamate or activated ester unit which may be present at the free E-terminus of the pseudo-PEG chain constituting unit A is reactive with respect to compounds having a complementary reactive unit such as an amine function (generally a primary amine aliphatic). Moreover, the primary amine function which may alternatively be present at the free E-terminus of the pseudo-PEG chain constituting unit A is reactive with respect to compounds having a complementary unit such as a carbamate or an activated ester .
- This end E1 allows in particular the fixation of biological macromolecules which comprise, naturally or not, said complementary reactive functions (antibodies, nucleic acids or analogs, polysaccharides, proteins, peptides, radionuclides, toxins, enzyme inhibitors, haptens, etc.). .).
- unit B after possible activation, that is to say after deprotection in the case of the oxyamine function or after unmasking in the case of the aldehyde function, under mild conditions compatible with the stability of the various partners involved, is reactive vis-à-vis compounds or materials having one or more carbonyl groups (aldehyde, ...) or alternatively amine.
- aldehyde Among such compounds, mention may in particular be made of macromolecules such as antibodies, nucleic acids or the like, liposomes, polysaccharides, proteins, peptides, active principles, radionuclides, toxins, fluorophores, enzyme inhibitors, haptens, etc.
- the thiol unit defined as a possible side substituent for the ⁇ -amino acid constituting the unit C is reactive with respect to the compounds or materials comprising a maleimide or iodoacetyl unit.
- the maleimide and iodoacetyl units, defined as possible side substituents of the ⁇ -amino acid constituting the unit C, are reactive with respect to the compounds or materials having a thiol function or a cysteine after their possible deprotection.
- the azide unit defined as possible lateral substituent of the ⁇ -amino acid constituting the unit C is reactive with respect to the compounds or materials having a true alkyne unit, phosphane or cyclooctyne and alternatively the true alkyne units, phosphane or cyclooctyne defined as possible side substituents of the ⁇ -amino acid constituting unit C are reactive with respect to compounds or materials having an azide pattern.
- This reaction site can in particular be used for the attachment of a fluorophore group carrying a complementary functional group reactive with the thiol, maleimide iodoacetyl, azide, true alkyne, phosphane or cyclooctyne units present on the C unit.
- the pseudo-PEG chain of unit A is chosen from the following chains of formula (A-I):
- Ri represents a primary amine, an activated carbamate unit or an activated ester unit
- n identical or different, are integers between 2 and 10 inclusive,
- p is an integer from 1 to 10 inclusive
- the arrow represents the covalent bond connecting the amide function of the E2 end of the pseudo-PEG chain to the unit B or C.
- activated carbamate groups that may be present at the E1 end of the pseudo-PEG chain of unit A, mention may in particular be made of N-hydroxysuccinimidyl carbamate, N-hydroxysuccinimidyl carbamate, N-carbamate and the like. hydroxyphthalimidyl, N-hydroxypiperidinyl carbamate, ⁇ -nitrophenyl carbamate and pentafluorophenyl carbamate; N-hydroxysuccinimidyl carbamate being very particularly preferred.
- the activated ester groups that may be present at the E1 end of the pseudo-PEG chain of unit A, there may be mentioned in particular the N-hydroxysuccinimidyl ester, the N-hydroxysuccinimidyl sulfo ester, the ester cyanomethyl, the N-hydroxyphthalimidyl ester, the N-hydroxypiperidinyl ester, the p-nitrophenyl ester, the pentafluorophenyl ester, the benzotriazole esters, the hydroxybenzotriazole esters and the hydroxyazabenzotriazole esters; the N-hydroxysuccinimidyl ester being particularly preferred.
- DABA 2,4-diaminobutanoic acid
- lysine is particularly preferred.
- ⁇ -amino acids which can be used for unit C, there may be mentioned in particular lysine, cysteine, homolysine, ornithine, 2,4-diaminobutanoic acid (DABA), 2,3-diaminobutanoic acid (DABA), diaminopropanoic acid, aminomercaptoacetic acid, Thomocysteine, 5-mercapto-norvaline, 6-mercapto-norleucine, 2-amino-7-mercapto-heptanoic acid, and 2-amino-8-mercaptoacetic acid; octanoic.
- DABA 2,4-diaminobutanoic acid
- DABA 2,3-diaminobutanoic acid
- diaminopropanoic acid aminomercaptoacetic acid
- aminomercaptoacetic acid Thomocysteine, 5-mercapto-norvaline, 6-mercapto-norleucine, 2-amin
- lysine and cysteine are particularly preferred.
- the protective groups for the oxyamine function of the side chain of the ⁇ -amino acid constituting the unit B are preferably chosen from labile protective groups under mild conditions such as 9-fluorenylmethoxycarbonyl (Fmoc), benzyloxycarbonyl (Z ), allyloxycarbonyl (Alloc), trichloroethoxycarbonyl (Troc), trimethylsilylethoxycarbonyl (Teoc), pyridyldithioethoxycarbonyl (Pydec), 2- (2-nitrophenyl) -propyloxycarbonyl ( ⁇ PPOC), azomethyloxycarbonyl (Azoc), 2 - (trimethylsilyl) ethanesulfonyl (Ses) and phthalimide.
- labile protective groups under mild conditions such as 9-fluorenylmethoxycarbonyl (Fmoc), benzyloxycarbonyl (Z ), allyloxycarbonyl
- the groups Fmoc and phthalimide are particularly preferred.
- the term "masked aldehyde function" any aldehyde or ketone function included in a molecule organic compound selected from serine or any organic molecule containing the 1,2-diol (-CH (OH) -CH (OH) -), 1,2-amino-alcohol or 1,2-hydroxythiol moiety.
- organic molecules there may be mentioned tartaric acid, glyceric acid, 2,3-dihydroxypropanoic acid, 3,4-dihydroxybutanoic acid, 4,5-dihydroxypentanoic acid and the acid. 3-amino-2-hydroxypropanoic acid.
- the term "mild conditions" the use of oxyamine function deprotection reagents or unmasking function of the aldehyde function at room temperature and at neutral pH or in a pH range between about 5 and 9 inclusive.
- HIO 4 periodic acid
- NaIO 4 sodium metaperiodate
- KIO 4 potassium metaperiodate
- R 1, m, n and p have the same meanings as those indicated above for the unit of formula (A-I),
- Proc is a protecting group selected from 9-fluorenylmethoxycarbonyl (Fmoc), benzyloxycarbonyl (Z), allyloxycarbonyl (Alloc), trichloroethoxycarbonyl (Troc), trimethylsilylethoxycarbonyl (Teoc), pyridyldithioethoxycarbonyl (Pydec), 2- ( 2-nitrophenyl) -propyloxycarbonyle (NPPOC), azomethyloxycarbonyl (Azoc), 2- (trimethylsilyl) ethanesulfonyl (Ses) and phthalimide;
- - Func is a thiol, maleimide, iodoacetyl, azide, true alkyne, phosphane or cyclooctyne unit.
- Xi is an n-butyl chain.
- X 2 is an ethyl or n-butyl chain.
- the compounds of formula (I) above are chosen from the following compounds of formulas (I-1) to (1-6):
- the trifunctional reagents according to the invention can be prepared according to convergent synthesis methods according to which each of the units A, B and C is prepared individually, these being then assembled to lead to the expected trifunctional reagent.
- These convergent synthesis methods implement conventional reactions well known to those skilled in the art and the details of which are given in the synthesis examples illustrating the present application.
- the reagents according to the present invention and as described above can have multiple uses and applications.
- the trifunctional reagents according to the present invention can firstly be used for the preparation of bioconjugates.
- Another object of the present invention is the use of at least one trifunctional reagent as defined above for the preparation of a bioconjugate.
- bioconjugate means any trifunctional reagent as described above on which at least one biological molecule of interest is attached.
- the fixation of the molecule (s) of interest may be carried out at the level of the primary amine function or the activated carbamate or activated ester unit present at the free end of the pseudo-PEG chain constituting the unit A which is reactive vis-a-vis the with respect to biological molecules having an acid function (or carbamate) or a reactive amine function (generally an aliphatic primary amine).
- the binding of the biological molecule of interest can also be carried out at unit B, after deprotection of the oxyamine function or unmasking of the aldehyde function, which then become reactive with respect to the biological molecules having one or more carbonyl groups (aldehyde, etc.) respectively oxyaminated. It is thus possible to set one or two biological molecules, identical or different, trifunctional reagent according to the present invention.
- Another object of the invention is thus a bioconjugate characterized in that it consists of a trifunctional reagent as defined above in which the primary amine unit, activated carbamate or activated ester present at the free end of the pseudo-chain.
- PEG constituting the unit A and / or the oxyamine or aldehyde function carried by the unit B after deprotection or unmasking is (are) functionalized by a biological molecule of interest.
- bioconjugates it is therefore possible to have the following three types of bioconjugates: i) a bioconjugate constituted by a trifunctional reagent in which only the amine function or only the activated carbamate or activated ester unit present at the free end of the pseudo chain -PEG constituting the unit A is functionalized by a biological molecule, ii) a bioconjugate constituted by a trifunctional reagent in which only the deprotected oxyamine or aldehyde function unmasked from the unit B is functionalized by a biological molecule, and iii) a bioconjugate comprising two biological molecules, constituted by a trifunctional reagent in which the primary amine function or the activated carbamate or activated ester unit present at the free end of the pseudo-PEG chain constituting the unit A and the deprotected oxyamine or aldehyde function unmasked from unit B are each functionalized by a biological molecule; in the latter case the bioconjugate comprises two
- bioconjugates can be made conventionally by reacting a trifunctional reagent according to the invention with the biological molecule or molecules of interest to be fixed, while using the methods well known in the technical state for reacting by example:
- the tri functional reagents according to the present invention can also be used for the preparation of luminescent reagents, in particular fluorescent reagents.
- Another object of the present invention is therefore the use of at least one trifunctional reagent as defined above, for the preparation of a luminescent reagent, in particular fluorescent reagents.
- the grafting of a luminescent group (L) can be carried out: i) by reacting the thiol, maleimide, iodoacetyl, azide, true alkyne, phosphane or cyclooctyne unit carried by the unit C with a maleimide complementary function , iodoacetyl (if unit C has a thiol function), thiol (if unit C has a maleimide or iodoacetyl unit) or true alkyne, phosphane or cyclooctyne (if unit C has an azide function), or else azide (if the unit C comprises a true alkyne function, phosphane or cyclooctyne), said complementary function being carried, naturally or not, by said luminescent group, and / or ii) by reacting the deprotected oxyamine or aldehyde function unmasked from the unit B with
- luminescent reagents comprising: i) a single luminescent group attached to the unit B via the deprotected oxyamine function or the unmasked aldehyde function or on the unit C via the thiol function or maleimide, iodoacetyl, true alkyne, phosphane, cyclooctyne or even azide units; ii) two luminescent groups, one being attached to the unit B via the deprotected oxyamine function or the unmasked aldehyde function and the other being attached to the unit C via the thiol function or maleimide, iodoacetyl, true alkyne, phosphane, cyclooctyne or even azide units.
- the nature of the luminescent group or groups that can be used according to the invention is not critical from the moment when they naturally comprise or are functionalisable by a thiol or carbonyl function, or by a maleimide, iodoacetyl or alkyne unit. true, phosphane, cyclooctyne or even azide.
- the term luminescent group any substance which, when excited at a given wavelength or by a given chemical compound, is capable of emitting a photon, for example fluorophore or rare earth.
- luminescent groups including fluorophores
- fluorophores with polymethine chains (ie polyene chain); fluorescent cyanines such as those sold under the references Cy3, Cy3.5, Cy3B, Cy5, Cy5.5 and Cy7 by the company GE Healthcare; fluorescein (sodium fluorescein) and its derivatives such as fluorescein isothiocyanate (FITC) and 6-carboxyfluorescein (6-Fam); rhodamine and its derivatives such as tetramethyl rhodamine isothiocyanate (TRITC); water-soluble derivatives of rhodamine in the form of N-hydroxysuccinimide ester, such as the products sold under the trade name Alexa Fluor® by Invitrogen, for example Alexa Fluor® 488, 500, 514, 532, 546, 555, 568, 594, 610-X, 633, 647, 660, 6
- the trifunctional reagents according to the present invention can also be used for the preparation of reagents luminescent, in particular fluorescent, also comprising an "acceptor compound" (Q) of the luminescence of the luminescent group
- reagents constitute what is known as an energy transfer cassette (or FRET cassette ) usable especially for the sequencing of DNA.
- Another object of the present invention is therefore the use of at least one trifunctional reagent as defined above for the preparation of a power transfer cassette.
- the grafting of the luminescent group will be carried out on the deprotected oxyamine or aldehyde function unmasked from the unit B or via the thiol function or the maleimide, iodoacetyl, true alkyne, phosphane, cyclooctyne or even azide units of the unit C, and the grafting of the acceptor compound (Q) will be carried out respectively via the thiol function or the maleimide, iodoacetyl, true alkyne, phosphane, cyclooctyne or even azide units of the unit C or on the deprotected or aldehyde oxyamine function unmasked from unit B.
- the invention therefore also relates to a transfer cassette of energy, characterized in that it consists of a trifunctional reagent as defined above, said reagent comprising a luminescent group (L) and an acceptor compound (Q ) of the luminescence of the luminescent group, L and Q being respectively and indifferently fixed on said trifunctional reagent via the deprotected oxyamine or aldehyde function unmasked from the unit B and the function thiol or the units maleimide, iodoacetyl, true alkyne, phosphane, cyclooctyne or even azide unit C.
- a transfer cassette of energy characterized in that it consists of a trifunctional reagent as defined above, said reagent comprising a luminescent group (L) and an acceptor compound (Q ) of the luminescence of the luminescent group, L and Q being respectively and indifferently fixed on said trifunctional reagent via the deprotected oxyamine or aldeh
- the luminescent group (L) that can be used in these energy transfer cassettes may in particular be chosen from the luminescent groups (L) mentioned above and that can be used for the preparation of the luminescent trifunctional reagents in accordance with the present invention.
- the term "acceptor compound" (Q) is understood to mean any molecule making it possible to reduce or disappear the luminescence of the luminescent group (L) under certain conditions.
- This compound of various natures, can in particular be a chemical compound (luminescent or not and such as for example fluorescent proteins), a heavy atom or a nanoparticle.
- acceptor compounds Q
- fluorescent compounds such as those mentioned above for L groups, in particular rhodamine and its derivatives such as tetramethyl rhodamine (TMR) and Rhodamine 6G (R6G).
- TMR tetramethyl rhodamine
- R6G Rhodamine 6G
- QSY® 7, QSY® 9 and QSY® 21 dyes (Molecular Probes); but also non-fluorescent molecules of the family of azo dyes, such as the compounds sold under the trade names Black HoIe Quencher® (BHQ), for instance BHQ-O, BHQ-I, BHQ-2 and BHQ-3 (Biosearch Technologies); gold particles such as those having a diameter of 1.5 nm sold under the trade name Nanogold Particles ® (Nanoprobes); disazo dyes such as the products sold under the trade names Eclipse Dark Quencher® (Epoch Bioscience) or QSY® 35 (Molecular Probes); the ElleQuencher ® commercial product (Eurogentec); malachite green and the acceptor compounds ("Quenchers") of the cyanine family, such as the compounds sold under the trade names Cy5Q or Cy7Q by the company GE Healthcare.
- BHQ Black HoIe Quencher®
- BHQ-O BHQ-O
- BHQ-I BHQ-2 and BHQ-3
- the luminescent group (L) and the acceptor compound (Q) are chosen from the following pairs (L / Q): Cy3 / Cy5, Cy5 / Cy7, Cy5 / Alexa Fluor ® 750, Cy3 / Cy5Q, Cy3 / QSY ® 7, Cy3 / QSY ® 9, Cy5 / Cy7Q, Cy5 / QSY ® 21, Cy5 / Cy5, Cy5.5 / Cy5.5, Cy7 / Cy7, R6 ) / Cy5, R6G / Alexa Fluor ® 647, R6G / QSY ® 21, Alexa Fluor ® 532 / Cy5, Alexa Fluor ® 532 / Alexa Fluor ® 647, Alexa Fluor ® 532 / QSY ® 21, Alexa Fluor ® 555 / Cy5, Alexa Fluor ® 555 / Alexa Fluor ® 647, Alexa Fluor ® 555 / Cy5, Alexa Fluor ® 555 /
- the trifunctional reagents can be used for the preparation of mixed bioconjugates comprising at least one biological molecule and at least one luminescent group.
- the present invention therefore also relates to a mixed bioconjugate, characterized in that it consists of a trifunctional reagent as defined above on which are fixed at least one biological molecule and at least one luminescent group.
- these mixed bioconjugates may also comprise an acceptor compound (Q) for the luminescence of the luminescent group (L).
- These mixed bioconjugates are therefore chosen from the trifunctional reagents on which are fixed: i) one or two biological molecules of interest and a luminescent group; or ii) a biological molecule of interest, and two luminescent groups; iii) a biological molecule of interest, a luminescent group, and an acceptor compound (Q) of the luminescence of the luminescent group; said biological molecules and said luminescent moieties and acceptor compound (Q) being attached to the functional reagent at the terminal ends of units A, B and C as described above.
- Trifunctional reagents and bioconjugates according to the present invention modified or not by a luminescent group at unit C, and in which the oxyamine or aldehyde function of unit B is free (ie non-functionalized by a biological molecule of interest, a fluorescent group or an acceptor compound) can be used for the functionalization of solid supports comprising at least one surface having one or more carbonyl groups, in particular one or more aldehyde or ketone functions or one or more oxyamine functions, respectively.
- the subject of the present invention is also a solid support, characterized in that it comprises at least one surface functionalized, covalently, with one or more trifunctional reagents, and / or with one or more bioconjugates, said reagents trifunctional and bioconjugated being optionally modified by a luminescent group at the level of the unit C and as defined above.
- the nature of the solid support is not critical from the moment when it comprises at least one surface having, naturally or after chemical modification, one or more carbonyl groups, in particular one or more aldehyde or ketone functions or respectively one or more primary amine functions, said groups or functions being able to react with the deprotected oxyamine function or respectively with the unmasked aldehyde function of the unit B of the tri functional reagent or the bioconjugate.
- Such supports there may be mentioned glass, plastic, and metals.
- the solid support comprises at least one surface functionalized with at least one bioconjugate and then constitutes a biochip such as for example a nucleic acid chip, a protein chip, a polysaccharide chip or a peptide chip, or a biosensor such as for example an immunosensor.
- a biochip such as for example a nucleic acid chip, a protein chip, a polysaccharide chip or a peptide chip, or a biosensor such as for example an immunosensor.
- Such supports can be prepared according to a process comprising the following steps: deprotection of the protected oxyamine function, or respectively the unmasking of the masked aldehyde function, present on unit B of at least one trifunctional reagent or from less a bioconjugate according to the invention to obtain a trifunctional reagent or a bioconjugate bearing a deprotected oxyamine function, respectively undefined aldehyde, - the formation of an oxyme bond by contacting said reagent or said bioconjugate carrying the oxyamine function deprotected or respectively aldehyde unmasked with a solid support of which at least one surface has a or more carbonyl groups, respectively primary amine, said oxyme bond ensuring the covalent attachment of said reagent or said bioconjugate to the surface of the support.
- Such supports may in particular be used for the detection of molecules of interest, in particular for the detection of analytes in a liquid medium.
- the invention also relates to the use of at least one trifunctional reagent as described above for the preparation of a probe for functional proteomics.
- Another object of the present invention is therefore a probe for functional proteomics, characterized in that it consists of a trifunctional reagent comprising:
- reporter tag a group allowing detection (or visualization) and / or purification of a target protein (reporter tag or "reporter tag”)
- the target protein is an enzyme
- the pattern recognized by the enzyme and the reactive group allowing a covalent link with the active site of this enzyme belong to the same entity.
- the other two units of said trifunctional reagent can be used to fix a group allowing detection (fluorophore for example) and a group facilitating purification (biotin, poly tag (histidine), ).
- the three entities can be fixed indifferently on any unit of the trifunctional pseudopeptide reagent according to the invention.
- the pattern recognized by the enzyme and the reactive group do not belong to the same entity and are therefore carried by two distinct units of the trifunctional pseudopeptide reagent according to the invention.
- the last unit of the trifunctional pseudopeptide reagent according to the invention will be used to fix the group allowing detection and / or purification.
- the unit A is a pseudo-PEG binding arm having an activated carbamate unit reactive with respect to the compounds having a primary amine function
- unit B is a lysine bearing on its side chain an oxyamine function protected by a Fmoc group, reactive with respect to surfaces having aldehyde functions
- - Unit C is a lysine having on its side chain a maleimide unit, reactive vis-à-vis the compounds having a thiol function.
- the strategy for synthesizing the compound (1-1) consists in separately preparing three correctly protected precursors (AI), (BI) and (CI) and then assembling them via coupling reactions to obtain the trifunctional reagent of formula (I-1 ) above according to the present invention.
- the precursor (AI) is a hydrophilic linker having four ethylene glycol units as well as a carboxylic acid function which will allow the subsequent coupling with the units (BI) and (CI) and a primary amino function that it It is essential to keep protected until the last conversion stage to "activated carbamate". It results from the combination of two molecules of 8-amino-3,6-dioxaoctanoic acid, said molecules having been prepared according to the methods described by Rensen, PC N et al, J. Med. Chem., 2004, 47, 5798-5808; Dondoni, A. et al, J. Org. Chem., 2005, 70, 5508-5518 or Dhawan, R.
- the reaction mixture was then acidified by adding about 25 ml of a 1 M aqueous potassium hydrogen sulfate solution (KHSO 4 ). This solution was then extracted with 3 times 50 ml of ethyl acetate. The organic phase was dried over sodium sulphate (Na 2 SO 4 ) and then evaporated to dryness. The resulting oily residue was purified by column chromatography on silica gel (40 g) using a gradient of methanol (0 to 6%) in CH 2 Cl 2 as the mobile phase. Compound (7) (0.50 g, 1.87 mmol) was obtained as a colorless oil (50% yield).
- KHSO 4 a 1 M aqueous potassium hydrogen sulfate solution
- the precursor (BI) was synthesized in two steps from the protected N-Fmoc derivative of the aminooxyacetic acid (8) previously prepared by reaction between the commercial aminooxyacetic acid and the chloroformate of 9-fluorenylmethanol under Schotten-Baumann conditions (Cipolla L. et al, Bioorg Med Chem, 2002, 10, 1639-1646).
- the precursor (CI) was synthesized in four steps from ⁇ -Boc- ⁇ -ZL-lysine (11); in this compound Z represents the benzyloxycarbonyl group.
- the carboxylic acid function is converted to carboxamide (12) by reaction of ammonia with the mixed anhydride intermediately formed according to the method described, for example, by Hofmann, K. et al., J. Am. Chem. Soc., 1978, 100, 3585-3590.
- the ⁇ -NH 2 function protected by a Z group was released (13) by catalytic hydrogenation in order to be able to couple the maleimide derivative of glycine (14) previously prepared by reaction between glycine and N- (methyloxycarbonyl) maleimide according to the method described by Keller O. et al, HeIv. Chim. Acta, 1975, 58, 531-541.
- the maleimide derivative (15) was then isolated by chromatography on silica gel with a yield of 51%. Finally, the N-terminus was deprotected by treatment with trifluoroacetic acid to yield the precursor (CI).
- a voluminous white precipitate immediately formed; this was recovered by filtration and washed with 25 ml of distilled water and then with 25 ml of pentane. The residual water was removed by lyophilization to yield 0.705 g (1.86 mmol) of the compound (12).
- the filtrate was, moreover, taken up in 20 ml of ethyl acetate, washed with 20 ml of distilled water, dried over Na 2 SO 4 and evaporated to dryness.
- the white solid obtained was washed with twice 25 ml of pentane and dried under vacuum. An additional amount of compound (12) (0.25 g, 0.66 mmol) was thus obtained. The total yield was 95%.
- N-Maleoyl-L-Glycine (14) 0.5 g of glycine (6.7 mmol) was dissolved in aqueous NaHCO 3 (2.8 g in 32 ml) and the solution was then cooled to room temperature. 0 ° C (NaCl / ice bath).
- the TFA was then evaporated and the product was precipitated with ether, washed with ether and lyophilized.
- the crude TFA salt of precursor (CI) was purified by reversed-phase flash chromatography on a grafted silica column Ci 8 (20 g, elution with an aqueous solution of 0.1% TFA). Fractions containing the product were lyophilized to give 91 mg (0.22 mmol, 27% yield) of the expected precursor (Cl) as a white solid.
- the trifunctional compound (1-1) was synthesized in 5 steps from the precursors (AI), (BI) and (CI) prepared above in the previous steps.
- the synthesis protocol of the compound (1-1) is summarized (the three main steps only) in the following scheme 2:
- the coupling between the precursors (BI) and (CI) was carried out after pre-activation of the precursor (BI) in the form of hydroxysuccinimide ester according to the method described for example in the article by Knorr, R. et al. Tetrahedron Lett., 1989, 30, 1927-1930.
- the activated ester was then reacted with the precursor (CI) to yield a coupling product (16) which was isolated by silica gel chromatography in 32% yield.
- treatment with TFA made it possible to eliminate the Boc group and thus obtain the precursor (BlC-1).
- the final coupling between the precursor (AI) and the precursor (BlC-1) was carried out using the BOP as a coupling reagent.
- the expected product in still protected form, was purified by chromatography on silica gel. After deprotection, by treatment with trifluoroacetic acid, the N-terminus was converted to activated carbamate by treatment with TV, 4'-disuccinimidyl carbonate (DSC) in anhydrous DMF in the presence of triethylamine. Total conversion of the pseudo-peptide to the compound of formula (I-1) was observed after 30 minutes.
- the compound of formula (1-1) expected was then purified by flash reverse phase chromatography on a grafted silica column Ci 8 .
- 0.2 g (0.36 mmol) of the precursor (BI) obtained above in step 2) d) were dissolved in 2 ml of anhydrous acetonitrile. 67.4 ⁇ l (0.38 mmol) of DIEA and 1.16 mg (0.38 mmol) of O- (N-succinimidyl) -N, N, N ', N'-tetramethyl-uronium tetrafluoroborate were then added. (TSTU) and the reaction mixture was stirred at room temperature for 45 minutes under an argon atmosphere. The conversion of the precursor (BI) to its N-hydroxysuccinimide ester was monitored by TLC (CH 2 Cl 2 / MeOH, 85:15, v / v).
- Example 1 a convergent synthesis strategy, as in Example 1) of separately preparing the precursors (A), (B) and (C) and to assemble them.
- precursor (A) the precursor (AI) synthesized in Example 1) above was used.
- precursor (B) a precursor of formula (BI) was synthesized in a substantially different route and improved with respect to that used for the synthesis of the precursor (BI) of Example 1).
- the synthesis of the precursor (C-2) was carried out from the commercial Boc-Cys (SEt) -OH. 1) Synthesis of the Precursor (BI): ⁇ -Frn-butyloxyearbonyl-1-fluorenylmethyloxycarboxyl-aminooxy-acetyl-L-lysine
- the precursor (B-I) was synthesized from the protected N-Fmoc derivative of the aminooxyacetic acid (8) previously prepared as in Example 1), step 2) a).
- the precursor (C-2) was synthesized in two steps from 7V- (tert-butyloxycarbonyl) -S- (S-ethyl) -cysteine (19) according to scheme 3 below:
- the carboxylic acid function of the compound (19) is converted into carboxamide (20) by reaction of the ammonia with the mixed anhydride intermediately formed according to the method described for example by Hofmann, K. and al, J. Am. Chem. Soc., 1978, 100, 3585-3590.
- the N-terminus of the compound (20) is deprotected by treatment with trifluoroacetic acid to yield the precursor (C-2).
- the compound (20) obtained above in the preceding step was slowly dissolved in 14 ml of a mixture of TFA / H 2 O (95: 5 v / v) with stirring at a temperature of between 0 ° C. and room temperature for 1 hour.
- the reaction was checked by TLC (CH 2 Cl 2 / MeOH 90:10 v / v) and the reaction mixture was evaporated to dryness. A minimum amount of osmosis water was then added and the resulting aqueous solution was lyophilized to yield the precursor (C-2) as a yellowish powder with a yield of 89%.
- the reagent (1-2) was synthesized in three steps from the precursors (A-I), (B-I) and (C-2) previously synthesized according to scheme 4 below:
- the coupling between the precursors (BI) and (C-2) was carried out after pre-activation of the precursor (BI) in the form of hydroxybenzotriazole ester according to the method described for example in the article by Konig, W. and al, Chem. Ber., 1970, 103, 788-798.
- the activated ester was then reacted with the precursor (CI) to yield a coupling product (21).
- a base DIEA
- the intermediate (BlC-2) was purified by chromatography on silica gel with a yield of 61%.
- the expected compound (22) was purified by HPLC-PI (System C, i.e. using a Varian column Kromasil ® Ci 8 to 10 microns and of dimensions 21.2 x 250 mm eluting with a mixture of acetonitrile and water osmosis by passing 90% of RO water for 5 minutes, then a linear gradient ranging from 10 to 40% of CH 3 CN in 15 minutes, then from 40% to 70% of CH 3 CN, with a flow rate of 20.0 ml / min, a dual UV detection was made at 254 and 305 nm) .
- HPLC-PI System C, i.e. using a Varian column Kromasil ® Ci 8 to 10 microns and of dimensions 21.2 x 250 mm eluting with a mixture of acetonitrile and water osmosis by passing 90% of RO water for 5 minutes, then a linear gradient ranging from 10 to 40% of CH 3 CN in 15 minutes, then from 40% to 70% of CH 3 CN, with
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010515552A JP2010533291A (ja) | 2007-07-11 | 2008-07-10 | 三官能性擬ペプチド試薬、ならびにその使用および適用 |
| EP08836332A EP2178834A1 (fr) | 2007-07-11 | 2008-07-10 | Reactif pseudo peptidique trifonctionnel, ses utilisations et applications |
| CA2694843A CA2694843A1 (fr) | 2007-07-11 | 2008-07-10 | Reactif pseudo peptidique trifonctionnel, ses utilisations et applications |
| US12/668,518 US20100221749A1 (en) | 2007-07-11 | 2008-07-10 | Three-functional pseudo-peptidic reagent, and uses and applications thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0705018 | 2007-07-11 | ||
| FR0705018A FR2918664B1 (fr) | 2007-07-11 | 2007-07-11 | Reactif pseudo peptidique trifonctionnel, ses utilisations et applications. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2009043986A1 true WO2009043986A1 (fr) | 2009-04-09 |
Family
ID=39272948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FR2008/001007 Ceased WO2009043986A1 (fr) | 2007-07-11 | 2008-07-10 | Reactif pseudo peptidique trifonctionnel, ses utilisations et applications |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100221749A1 (fr) |
| EP (1) | EP2178834A1 (fr) |
| JP (1) | JP2010533291A (fr) |
| CA (1) | CA2694843A1 (fr) |
| FR (1) | FR2918664B1 (fr) |
| WO (1) | WO2009043986A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014031635A1 (fr) | 2012-08-21 | 2014-02-27 | Ortho-Clinical Diagnostics, Inc | Anticorps dirigés contre des haptènes d'aripiprazole et leur utilisation |
| US9504682B2 (en) * | 2012-08-21 | 2016-11-29 | Janssen Pharmaceutica Nv | Haptens of aripiprazole |
| CN106928086B (zh) | 2015-12-31 | 2019-05-31 | 深圳翰宇药业股份有限公司 | 一种长链化合物的制备方法 |
| US11175228B2 (en) * | 2018-11-28 | 2021-11-16 | Promega Corporation | Reactive peptide labeling |
| CN117185950A (zh) * | 2023-09-08 | 2023-12-08 | 安徽昊帆生物有限公司 | Aeea-aeea的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000002050A1 (fr) * | 1998-07-07 | 2000-01-13 | Department Of Radiation Oncology, University Of Washington | Reactif trifonctionnel pour la conjugaison avec une biomolecule |
| WO2006064505A2 (fr) * | 2004-12-15 | 2006-06-22 | Yeda Research And Development Co. Ltd. | Plate-forme a un seul etage pour integration sur puce de biomolecules |
-
2007
- 2007-07-11 FR FR0705018A patent/FR2918664B1/fr not_active Expired - Fee Related
-
2008
- 2008-07-10 EP EP08836332A patent/EP2178834A1/fr not_active Withdrawn
- 2008-07-10 US US12/668,518 patent/US20100221749A1/en not_active Abandoned
- 2008-07-10 JP JP2010515552A patent/JP2010533291A/ja not_active Withdrawn
- 2008-07-10 WO PCT/FR2008/001007 patent/WO2009043986A1/fr not_active Ceased
- 2008-07-10 CA CA2694843A patent/CA2694843A1/fr not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000002050A1 (fr) * | 1998-07-07 | 2000-01-13 | Department Of Radiation Oncology, University Of Washington | Reactif trifonctionnel pour la conjugaison avec une biomolecule |
| WO2006064505A2 (fr) * | 2004-12-15 | 2006-06-22 | Yeda Research And Development Co. Ltd. | Plate-forme a un seul etage pour integration sur puce de biomolecules |
Non-Patent Citations (4)
| Title |
|---|
| NAKATANI, KAZUHIKO ET AL: "Highly sensitive detection of GG mismatched DNA by surfaces immobilized naphthyridine dimer through poly(ethylene oxide) linkers", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 5, 2004, pages 1105 - 1108, XP002476892 * |
| VISINTIN, CRISTINA ET AL: "Membrane Receptor Probes: Solid-Phase Synthesis of Biotin-Asp-PEG-arvanil Derivatives", ORGANIC LETTERS, vol. 7, no. 9, 2005, pages 1699 - 1702, XP002476893 * |
| VOLLAND, HERVE ET AL: "Solid-phase immobilized tripod for fluorescent renewable immunoassay. A concept for continuous monitoring of an immunoassay including a regeneration of the solid phase", ANALYTICAL CHEMISTRY, vol. 77, no. 6, 2005, pages 1896 - 1904, XP002476891 * |
| WANG, ZHENGFU ET AL: "Convergent synthesis of ribonuclease L-active 2',5'-oligoadenylate- peptide nucleic acids", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 12, 2000, pages 1357 - 1360, XP002476894 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2694843A1 (fr) | 2009-04-09 |
| EP2178834A1 (fr) | 2010-04-28 |
| FR2918664B1 (fr) | 2009-10-02 |
| US20100221749A1 (en) | 2010-09-02 |
| FR2918664A1 (fr) | 2009-01-16 |
| JP2010533291A (ja) | 2010-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6942147B2 (ja) | Mt1−mmpに対して特異的な二環式ペプチド−毒素コンジュゲート | |
| US9329184B2 (en) | Fluorescent probe | |
| JP2020514403A (ja) | Mt1−mmpに結合するためのペプチドリガンド | |
| WO2010034931A1 (fr) | Nouveaux substrats d'o6-alkylguanine-adn alkyltransferase et ses mutants | |
| WO2013011236A1 (fr) | Nouveaux agents complexants et complexes de lanthanide correspondants | |
| WO2009043986A1 (fr) | Reactif pseudo peptidique trifonctionnel, ses utilisations et applications | |
| JP4098839B2 (ja) | インドシアニン化合物 | |
| Clavé et al. | A universal and ready-to-use heterotrifunctional cross-linking reagent for facile synthetic access to sophisticated bioconjugates | |
| EP1315739B1 (fr) | Procede de couplage, en solution, entre un peptide et un vecteur lipophile et ses applications | |
| EP3638659B1 (fr) | Nouveaux agents mono et di-antennes complexants hydrosolubles et complexes de lanthanide correspondants | |
| WO2008145830A2 (fr) | Nouveaux composes pro-fluorescents | |
| WO2010100238A1 (fr) | Agents de reticulation | |
| EP3386974B1 (fr) | Agents complexants hydrosolubles a base de triazapyridonophane et complexes de lanthanide fluorescents correspondants | |
| FR2952058A1 (fr) | Procede de ligation native de polypeptides | |
| EP2033663B1 (fr) | Substrats fluorescents saccharidiques, leur procédé de préparation et leurs utilisations | |
| FR2721612A1 (fr) | Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications. | |
| EP1904847B1 (fr) | Substrats fluorescents saccharidiques, leur procede de preparation et leurs utilisations | |
| EP2688960A1 (fr) | Composes à groupements chromophore et photoreactif | |
| WO2005063263A1 (fr) | Nouveaux derives de la morphine-6-glucuronide, compositions pharmaceutiques les contenant, leur procede de preparation et leurs utilisations | |
| CA2898081A1 (fr) | Derives amphiphiles de composes triazamacrocycles, produits et compositions les comprenant, leurs procedes de synthese et leurs utilisations | |
| FR3016630A1 (fr) | Reactif comprenant quatre fonctions orthogonales et ses utilisations | |
| EP2524229B1 (fr) | Procédé de préparation de composés polybiotinylés | |
| WO2000062072A1 (fr) | Methode homogene de detection mettant en jeu un cryptate de terre rare | |
| EP3191501A1 (fr) | Conjugués glucidiques fluorescents, leur procédé de préparation et leurs utilisations | |
| WO1991012268A1 (fr) | Nouveaux substrats peptidiques, procede de preparation et utilisation dans la determination de la proteine c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08836332 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2010515552 Country of ref document: JP Ref document number: 2694843 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008836332 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12668518 Country of ref document: US |